The mineralocorticoid receptor antagonist (MRA) eplerenone has been shown to improve
the prognosis of patients who had a myocardial infarction (MI) complicated with symptomatic …

Aim It is unknown whether safety and clinical endpoints by use of sacubitril/valsartan (an
angiotensin receptor–neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor …

Background Guidelines recommend mineralocorticoid receptor antagonist (MRA) use in
patients with left ventricular ejection fraction≤ 40% following a myocardial infarction plus …

Heart failure (HF) with reduced ejection fraction (HFrEF) and preserved ejection fraction
(HFpEF), and myocardial infarction (MI) complicated with systolic dysfunction have a poor …

Aims We investigated the incremental advantage in terms of N-terminal pro-B-type
natriuretic peptide (NT-proBNP) reduction in patients affected by heart failure with reduced …

MI complicated by left ventricular systolic dysfunction (LVSD) and HF. 2–5 Beyond these
neurohormonal antagonists, lipid-lowering drugs, new anti-platelet and anti-thrombotic …

Background There are no studies of mineralocorticoid receptor antagonist (MRA) treatment
examining outcome in unselected real‐life patients with myocardial infarction (MI) and heart …

Background Mineralocorticoid antagonists improve survival among patients with chronic,
severe systolic heart failure and heart failure after myocardial infarction. We evaluated the …

Heart failure (HF) is a syndrome characterized by the activation of several neurohormonal
mechanisms initially focused on maintaining an adequate peripheral perfusion, but …

The EMPHASIS-HF investigators have demonstrated that the addition of the selective
mineralocorticoid receptor antagonist (MRA), eplerenone, to standard evidence-based …